CLOVER CORPORATION LIMITED (CLV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CLV - CLOVER CORPORATION LIMITED

FNArena Sector : Health & Nutrition
Year End: July
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.42
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.47

20 Nov
2024

-0.010

OPEN

$0.49

-2.08%

HIGH

$0.49

79,751

LOW

$0.47

OTHER COMPANIES IN THE SAME SECTOR
EBO . EXL . MCP . SIG .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 30/10 - ex-div 0.75c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.9
DPS All xxxxxxxxxxxxxxx0.8
Sales/Revenue xxxxxxxxxxxxxxx62.2 M
Book Value Per Share xxxxxxxxxxxxxxx40.2
Net Operating Cash Flow xxxxxxxxxxxxxxx8.5 M
Net Profit Margin xxxxxxxxxxxxxxx2.44 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx2.26 %
Return on Invested Capital xxxxxxxxxxxxxxx2.02 %
Return on Assets xxxxxxxxxxxxxxx1.78 %
Return on Equity xxxxxxxxxxxxxxx2.26 %
Return on Total Capital xxxxxxxxxxxxxxx4.00 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx4.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx4 M
Long Term Debt xxxxxxxxxxxxxxx7 M
Total Debt xxxxxxxxxxxxxxx10 M
Goodwill - Gross xxxxxxxxxxxxxxx2 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx1.22

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx2.3 M
Capex % of Sales xxxxxxxxxxxxxxx3.74 %
Cost of Goods Sold xxxxxxxxxxxxxxx45 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx14 M
Research & Development xxxxxxxxxxxxxxx2 M
Investments - Total xxxxxxxxxxxxxxx11 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Taylor Collison

08/10/2024

1

Speculative Buy

-

-

Clover's FY24 results on September 26 revealed earnings (EBITDA) of $4m compared to Taylor Collison's $3.2m forecast due to a lower- than-anticipated research and development and marketing spend.

In order to protect the supply chain while also helping to improve gross margins, explains the broker, management announced the investment of -$5m in a fish oil extraction facility in Ecuador. The aim is to provide an internal source of fish oil.

While Clover leads the world in manufacturing of micro-encapsulated Docosahexaenoic Acid (DHA), the analysts note competition from increasing use of algal oil (produced on a large scale in China) in infant formula.

The Speculative Buy rating is maintained. No target price is set.

FORECAST
Taylor Collison forecasts a full year FY25 dividend of 1.20 cents and EPS of 3.30 cents.
Taylor Collison forecasts a full year FY26 dividend of 1.80 cents and EPS of 3.50 cents.
Access Extra Coverage Research History >

CLV STOCK CHART

FNArena News on CLV

1
Australian Broker Call *Extra* Edition – Oct 08, 2024

Oct 08 2024 - Daily Market Reports
2
In Case You Missed It – BC Extra Upgrades & Downgrades – 12-04-24

Apr 12 2024 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Apr 08, 2024

Apr 08 2024 - Daily Market Reports
4
FNArena Corporate Results Monitor – 22-03-2024

Mar 22 2024 - Australia
5
Australian Broker Call *Extra* Edition – Mar 20, 2024

Mar 20 2024 - Daily Market Reports

Latest Health & Nutrition News

1
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
2
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
3
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
4
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
5
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
6
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
7
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
8
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
9
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
10
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia